Get the Stockscreener App
3.78
10.64%
-0.45
Prime Medicine Inc stock is traded at $3.78, with a volume of 6.65M.
It is down -10.64% in the last 24 hours and up +39.48% over the past month.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
See More
Previous Close:
$4.23
Open:
$4.2
24h Volume:
6.65M
Relative Volume:
2.24
Market Cap:
$682.73M
Revenue:
$4.63M
Net Income/Loss:
$-201.14M
P/E Ratio:
-2.7509
EPS:
-1.3741
Net Cash Flow:
$-167.10M
1W Performance:
-2.33%
1M Performance:
+39.48%
6M Performance:
-4.06%
1Y Performance:
-19.40%
1-Day Range:
$3.62
$4.265
1-Week Range:
$3.62
$4.825
52-Week Range:
$2.67
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.78 | 682.73M | 4.63M | -201.14M | -167.10M | -1.3741 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Initiated | Oppenheimer | Outperform |
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Prime Medicine Stock Dips As Traders Weigh Heavy Losses - timothysykes.com
Enterprise value to EBITDA forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
Prime Medicine gains after winning arbitration with Beam Therapeutics - MSN
PRME Stock Slides As Traders Weigh Heavy Losses And Cash Runway - StocksToTrade
Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
H.C. Wainwright reiterates Prime Medicine stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug - Tech Times
Prime Medicine wins arbitration to advance gene editing program, shares jump over 15%. - Pluang
Prime Medicine Beats Beam Therapeutics In Patent DisputeBut Both Are Investable (PRME) - Seeking Alpha
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating - Moomoo
Prime Medicine stock surges after winning arbitration with Beam - Investing.com
Prime Medicine, Inc. (NASDAQ:PRME) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Prime Medicine Jumps 15% as Arbitration Win Clears Path for AATD Gene-Editing Human Trials - finance.biggo.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win By Investing.com - Investing.com South Africa
Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise - marketscreener.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win - Investing.com India
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case - Benzinga
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
Prime Medicine wins binding arbitration against Beam Therapeutics - grafa.com
Prime Medicine Shares Rise on Positive Arbitration Ruling in Beam Dispute - Moomoo
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com Canada
Why is Prime Medicine stock surging today? By Investing.com - Investing.com Canada
Prime Medicine, Inc. Files Form 8-K With SEC – Company Details, Stock Info, and Compliance Highlights - Minichart
Prime Medicine Stock Pops As ARK, Analysts Back Gene Editor - StocksToTrade
Prime Medicine wins arbitration over AATD therapy PM647 - Investing.com
Prime Medicine wins arbitration over AATD therapy PM647 By Investing.com - Investing.com India
Prime Medicine wins arbitration ruling, PM647 found within its field; Beam's claims denied - TradingView
Prime Medicine (NASDAQ: PRME) cleared of breach in Beam arbitration ruling - Stock Titan
Prime Medicine clears Beam dispute, keeps PM647 for AATD - Stock Titan
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal - Yahoo Finance
Here’s Why H.C. Wainwright Upgraded Prime Medicine (PRME) To “Buy” - Yahoo Finance
10 Overlooked Penny Stocks to Buy Right Now - Insider Monkey
PRMEPrime Medicine Inc Options - Finviz
Enterprise value to revenue forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
PRME Q1 2026 Earnings: EPS Misses Estimates but Stock Gains on Pipeline ProgressEarnings Decline Risk - dars.gov.et
Enterprise value to EBIT forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 2500 Growth Benchmark - marketscreener.com
Price to book forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
Price to sales forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
H.C. Wainwright upgrades Prime Medicine stock rating to buy By Investing.com - Investing.com Nigeria
Prime Medicine, Inc.(NasdaqGM:PRME) added to Russell Microcap Growth Benchmark Index - marketscreener.com
H.C. Wainwright upgrades Prime Medicine stock rating to buy - Investing.com
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 2000 Growth Benchmark - marketscreener.com
H.C. Wainwright Upgrades Prime Medicine(PRME.US) to Buy Rating, Announces Target Price $8 - Moomoo
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 3000E Growth Benchmark - marketscreener.com
Prime Medicine, Inc.(NasdaqGM:PRME) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
PRME Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances Gene Editing PipelineFinancial Health Score - dars.gov.et
Prime Medicine, Inc. Actuals & Estimates (NASDAQ:PRME) - TradingView
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prime Medicine Inc Stock (PRME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):